| PRD_000488 | Name: | TRIOSTIN A | Formula: | C50 H62 N12 O12 S2 | Description: | TRIOSTIN IS A BICYCLIC OCTADEPSIPEPTIDE.
BICYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI, AND A DISULPHIDE BOND BETWEEN
RESIDUES 3 AND 7.
THE TWO QUINOXALINE CHROMOPHORES ARE LINKED
TO THE D-SERINE RESIDUES, RESIDUES 1 AND 5. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000491 | Name: | Echinomycin | Formula: | C51 H64 N12 O12 S2 | Description: | ECHINOMYCIN IS A BICYCLIC OCTADEPSIPEPTIDE.
BICYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI, AND A THIOACETAL BOND BETWEEN
RESIDUES 3 AND 7.
THE TWO QUINOXALINE CHROMOPHORES ARE LINKED
TO THE D-SERINE RESIDUES, RESIDUES 1 AND 5. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000492 | Name: | uk63052 | Formula: | C56 H68 N10 O14 S2 | Description: | QUINOMYCIN UK63052 IS A BICYCLIC OCTADEPSIPEPTIDE.
BICYCLIZATION IS ACHIEVED BY LINKING THE N- AND
THE C- TERMINI, AND A THIOACETAL BOND BETWEEN
RESIDUES 3 AND 7.
THE TWO HYDROXYQUINOXALINE CHROMOPHORES ARE LINKED
TO THE D-SERINE RESIDUES, RESIDUES 1 AND 5. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000503 | Name: | ADEP1 | Formula: | C38 H50 N6 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000504 | Name: | ADEP2 | Formula: | C41 H56 F2 N6 O8 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000505 | Name: | Quinupristin | Formula: | C53 H67 N9 O10 S | Description: | QUINUPRISTIN IS A CYLIC HEPTAPEPTIDE. THE RING GENERATED BY LINKING RESIDUE 2 SIDE-CHAIN IS AND MAIN-CHAIN RESIDUE 7. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000507 | Name: | PYOVERDIN C-E CHROMOPHORE | Formula: | C55 H86 N17 O22 | Description: | IN IRON-DEFICIENT CONDITIONS, PSEUDOMONAS AERUGINOSA SECRETES A MAJOR FLUORESCENT SIDEROPHORE NAMED PYOVERDIN (PVD),
WHICH AFTER CHELATING IRON(III) IS TRANSPORTED BACK INTO THE CELL VIA ITS OUTER MEMBRANE RECEPTOR FPVA. FPVA IS A
TONB-DEPENDENT TRANSPORT PROTEIN AND HAS THE ABILITY TO BIND PVD IN ITS APO- OR IRON-LOADED FORM. | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000553 | Name: | APSTATIN | Formula: | C23 H33 N5 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000555 | Name: | AERUGINOSIN 298-A | Formula: | C30 H48 N6 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-11-03 |
|
| PRD_000556 | Name: | AERUGINOSIN 98-B | Formula: | C29 H46 N6 O9 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000557 | Name: | Pepstatin | Formula: | C34 H63 N5 O9 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000558 | Name: | Chymostatin A | Formula: | C31 H41 N7 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000559 | Name: | Chymostatin | Formula: | C22 H32 N6 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000560 | Name: | [N2-[(S)-1-CARBOXY-3-PHENYLPROPYL]-L-LYSYL-L-PROLINE | Formula: | C21 H31 N3 O5 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000562 | Name: | (4R)-N-tert-butyl-3-[(2S,3S)-2-hydroxy-3-({N-[(isoquinolin-5-yloxy)acetyl]-S-methyl-L-cysteinyl}amino)-4-phenylbutanoyl]-1,3-thiazolidine-4-carboxamide | Formula: | C33 H41 N5 O6 S2 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000563 | Name: | N-[(2R)-1-{[(2S,3R,5R)-1-cyclohexyl-3-hydroxy-5-{[2-(morpholin-4-yl)ethyl]carbamoyl}oct-7-yn-2-yl]amino}-3-(methylsulfa
nyl)-1-oxopropan-2-yl]-1H-benzimidazole-2-carboxamide | Formula: | C33 H48 N6 O5 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000564 | Name: | N-(tert-butoxycarbonyl)-L-phenylalanyl-N-[(2S,3S,5R)-1-cyclohexyl-3-hydroxy-7-methyl-5-(methylcarbamoyl)octan-2-yl]-L-histidinamide | Formula: | C37 H58 N6 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000565 | Name: | N-[(2S)-1-[[(2S)-1-[[(2S,3R)-1-cyclohexyl-4,4-difluoro-3-hydroxy-5-(methylamino)-5-oxo-pentan-2-yl]amino]-1-oxo-hexan-2
-yl]amino]-1-oxo-3-phenyl-propan-2-yl]morpholine-4-carboxamide | Formula: | C32 H49 F2 N5 O6 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000566 | Name: | (4R)-3-{(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-N-(2-methylbenzyl)-1,3-thiazolidine-4-carboxamide | Formula: | C32 H37 N3 O5 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000567 | Name: | (4R)-N-tert-butyl-3-{(2S,3S)-2-hydroxy-3-[(3-hydroxy-2-methylbenzoyl)amino]-4-phenylbutanoyl}-5,5-dimethyl-1,3-thiazoli
dine-4-carboxamide | Formula: | C28 H37 N3 O5 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000568 | Name: | N-[(benzyloxy)carbonyl]-3-[(2,2-dimethylpropanoyl)amino]-L-alanyl-N-[(1R)-4-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}pentyl]-L-leucinamide | Formula: | C32 H49 N5 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000569 | Name: | N-[(benzyloxy)carbonyl]-O-tert-butyl-L-threonyl-N-[(1R)-4-cyclopropyl-4-oxo-1-{[(3S)-2-oxopyrrolidin-3-yl]methyl}butyl]-L-leucinamide | Formula: | C34 H52 N4 O7 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000571 | Name: | FR901451 | Formula: | C60 H80 N13 O18 | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000572 | Name: | (4R)-3-[(2R,3S)-3-{[(2,6-dimethylphenoxy)acetyl]amino}-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-
inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide | Formula: | C35 H41 N3 O6 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|
| PRD_000575 | Name: | (4R)-3-[(2S,3S)-3-{[(2,6-dimethylphenoxy)acetyl]amino}-2-hydroxy-4-phenylbutanoyl]-N-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]-5,5-dimethyl-1,3-thiazolidine-4-carboxamide | Formula: | C35 H41 N3 O6 S | Definition date: | 2012-12-12 | Last modified: | 2023-09-20 |
|